My "Holy Grail" Approaches

You are receiving this email because you signed up to receive our free e-letter, or you purchased a product or service from its publisher, Early Investing. If you are having trouble viewing this email, click here to view it in your browser.
What Blockchain Technology Can Do for You

By Andy Gordon, October 26, 2016

Dear Early Investor,

I have a dream...

That everybody can buy and sell shares of startups at any time and any place.

In a post last month, I described what this would look like...
Exchanges will soon be faster... as well as better at moving large amounts of money and matching sellers with buyers. Instant information on a company - even a small far-off one, in Nepal, say - won't be a problem. Instant access will be available to everybody on the cloud.
I called it the "holy grail"... a liquid market of private startup companies where billions of people around the world buy and sell shares.

And I said that by 2025 we "should be knocking on the door."

That's nine years away, not far off considering how creaky equity investing is and how illiquid startup investing is.

If anything, I thought I was being optimistic.

And it's true that I was way off. But not in the way you think.
Abandoning the USA Like Rats on a Sinking Ship

rat Right now, there's a list of 25 countries agreeing to take "revenge" on the USA due to a certain American economic practice.

Even allies Canada, Britain and Qatar appear on the list! If you think "friends" turning their backs on us is bad... you won't believe what our enemies are up to. Our friends at The Oxford Club have full details here.
It could happen much sooner than 2025.

The technology is becoming available much faster than I thought.

Take OneChronos. I've mentioned this interesting startup before. It graduated from Y Combinator this past summer. It uses sophisticated techniques, including algorithmic game theory, machine learning and cryptography, to match buyers and sellers.

And it wants to level the playing field by eliminating the need to race over a network to get into a trade microseconds early.

Both its founders - Stephen Johnson and Kelly Littlepage - were trained in computer science. I wish them the best of luck.

The Technology Behind Bitcoin

But there's another technology that may hold the key to overhauling today's exchanges.

It's "blockchain" tech - the same accounting system that powers bitcoin.

Blockchain's decentralized ledger system has the ability to transform the underpinnings of exchanges, performing cross-border equity trades at lightning speeds while providing unmatched security.

(If you're interested in learning more about how it works, I suggest you read this article to quickly get up to speed.)

A number of startups are now using the blockchain for payment processing and money transfers. Circle Internet Financial is just one example out of many.

And not long ago, the Nasdaq started experimenting with blockchain technology to automate trading of private shares.


But an unknown startup from Estonia may be beating it to the punch. It's called Funderbeam and it's headed by Kaidi Ruusalepp. She was previously CEO of the Nasdaq Tallinn stock exchange.

Using blockchain technology, it provides a transparent and trustworthy platform for secondary trading - letting shareholders sell their stakes in a startup.

And - true to my vision of an exchange that can provide "instant information on a company" - Funderbeam's platform is also part research tool.

Aside from the Nasdaq's cautious flirtation with blockchain technology, Funderbeam is the first company (as far as I know) to build a securities trading platform on the blockchain.

Ruusalepp says, "Imagine if Bloomberg, AngelList and Nasdaq had a baby."

But it won't be easy.

Confidential information is a problem of access, not technology. And the rules of almost every country, including the U.S., need to change to allow a global and frictionless cross-border exchange of securities to take place.

Blockchain technology has a plethora of applications. But we're at the very beginning of a long runway here. Even the blockchain's most proven and well-known application - bitcoin - has had setbacks and delays in being adopted.

Funderbeam's vision is incredibly ambitious. It won't happen overnight.

But the technology no longer seems to be the main obstacle. Rather - and this is no outrageous prediction by any means - it will be the governments of the world that fear the free flow of money and equity across borders.

But one step at a time. That's another subject altogether.

Invest early and well,

Andy Gordon
Founder, Early Investing
Click here to comment on EarlyInvesting.com Comment
3 New Wefunder Deals Reviewed
By Adam Sharp, October 21, 2016

Equity crowdfunding is hitting its stride. I continue to believe that this is the future of capital raising for startups and small business. Read on...
Five Clues to Early Killer Traction
By Andy Gordon, October 19, 2016

Here are five clues that point to possible killer traction before revenue takes off for startups. Read on...
Truly Investing vs. "Trading" Investing
By Adam Sharp, October 14, 2016

The average American investor makes just 2.5% per year in stocks. Find out why private investing may be better. Read on...


Nature Neuroscience Contents: November 2016 Volume 19 Number 11, pp 1381 - 1536

If you are unable to see the message below, click here to view.
Nature Neuroscience

Nikon invites you to visit www.seemorethanbefore.com for a sneak peek at our latest imaging innovation. Sign up to receive updates leading up to the big November 9 reveal, and be sure to visit the Nikon booth at the Neuroscience 2016 Meeting in San Diego to see the new system in action.

To See More Than Before, click here.

November 2016 Volume 19, Issue 11

News and Views
FREE TRIAL: New Neuropsychiatric Disorder Models For a limited time, validate Taconic Biosciences' new neuropsychiatric disorder models in your research facility for free.  

  • Models with chromosomal deletions orthologous to human 15q13.3, 22q11.2, or 1q21.1.
  • Useful for screening novel drug candidates for treating schizophrenia, autism spectrum disorders, epilepsy and other neuropsychiatric disorders.

Recommend to library

Nature Outlook: Lysosomal Storage Disorders

Lysosomal storage disorders are individually rare but collectively common. The study of these diseases is not only leading to better treatments, but also revealing many of the secrets of this underappreciated organelle. 

Access the Outlook >

Produced with support from: 
Alexion Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical Inc.

Produced with support of a grant from:
Shire plc
BioMarin Pharmaceutical Inc
nature.com webcasts

Springer Nature presents a custom webcast on: uDISCO for whole organs and organisms:
A new way of large sample imaging

Date: Thursday October 27, 2016

Register for FREE

Sponsored by:
LaVision Biotech
Andor Technology

Nature Human Behaviour
Covering the scope of human behavior
Nature Human Behaviour will publish research of outstanding significance into any aspect of human behaviour: its psychological, biological, and social bases, as well as its origins, development, and disorders.

Need access at your workplace or institution? 
Click here to recommend site license access to your librarian.


Focus on psychiatric disorders
Focus issue: November 2016 Volume 19, No 11



Focus on psychiatric disorders   pp1381 - 1382
Nature Neuroscience presents a Focus issue highlighting progress in basic and clinical sciences advancing mental health research.



Back to basics: luring industry back into neuroscience   pp1383 - 1384
Steven E Hyman
An obsession with producing and validating models (face, construct, predictive validity) has led many of us down a deep rabbit hole, thinking about models instead of mechanisms. Advances in the human genetics and neurobiology of brain disorders create exciting new opportunities, but only if we can get back to basics.



On being a circuit psychiatrist   pp1385 - 1386
Joshua A Gordon
Recent technological advancements in the study of neural circuits provide reasons to be optimistic that novel treatments for psychiatric illnesses are just around the corner. Maximizing the chances of translating these advancements into real improvements in patient care requires a carefully considered road map.

Psychiatric distress in animals versus animal models of psychiatric distress   pp1387 - 1389
Robert M Sapolsky
Primatology research suggests that other primates suffer from crippling depression or anxiety, implying that these diseases' roots pre-date human history. At the same time, some realms of psychiatry remain uniquely human. Recognizing the similarities and dissimilarities between us and other primates is essential in studying animal models of psychiatric disease.

The origin and natural history of autism spectrum disorders   pp1390 - 1391
James C Harris
Refined social phenotyping of syndromic and idiopathic forms of autism, combined with advances in genetics, animal models of syndromes and brain imaging, may facilitate discovery of shared brain mechanisms that will lead to new treatments. The reversal of social deficits in animal models is promising for eventual translation into therapeutics.

Translating genome-wide association findings into new therapeutics for psychiatry   pp1392 - 1396
Gerome Breen, Qingqin Li, Bryan L Roth, Patricio O'Donnell, Michael Didriksen et al.
The Psychiatric Genomics Consortium is aiming to analyze data from >1 million individuals. This is already leading to hundreds of new genetic findings across psychiatric disorders with the potential to restart largely stalled psychiatric drug development pipelines. This paper outlines key questions and plans to translate findings into new therapeutics.



The road to precision psychiatry: translating genetics into disease mechanisms   pp1397 - 1407
Michael J Gandal, Virpi Leppa, Hyejung Won, Neelroop N Parikshak and Daniel H Geschwind
Recently, robust identification of hundreds of genetic variants associated with risk for neuropsychiatric disease has prompted new challenges in understanding their biological impact within an individual. The authors provide a framework for interpretation of genetic risk variants to uncover disease mechanisms and facilitate therapeutic development.

Lessons learned from studying syndromic autism spectrum disorders   pp1408 - 1417
Yehezkel Sztainberg and Huda Y Zoghbi
Autism spectrum disorders are highly heterogeneous and include both idiopathic and syndromic forms. Sztainberg and Zoghbi discuss insights gained from studying syndromic autism spectrum disorders and their potential contribution to our understanding of the molecular pathways critical for normal cognitive and social development, as well as the relevance to idiopathic autism.

Using model systems to understand errant plasticity mechanisms in psychiatric disorders   pp1418 - 1425
Bruno B Averbeck and Matthew V Chafee
Animal models have failed to yield new treatments for psychiatric disorders. Some psychiatric disorders may result from pathology in plasticity mechanisms. Therefore, understanding plasticity mechanisms in model systems may provide insight into the disordered processes in patients.

News and Views


Rare variants are common in schizophrenia   pp1426 - 1428
Jacob Gratten
A large DNA sequencing study of schizophrenia finds more evidence that rare inherited coding mutations across many genes contribute to risk of the disorder. This has important implications for geneticists and neuroscientists alike.

See also: Article by Genovese et al.

Brains, genes and power   pp1428 - 1430
Frank W Albert
Gene expression data from more than 500 human brains shed light on the molecular consequences of genetic variation that contributes to schizophrenia.

See also: Article by Fromer et al.

When size matters: CHD8 in autism   pp1430 - 1432
Martin W Breuss and Joseph G Gleeson
Recent models studying loss of the mouse homolog of the autism-associated gene CHD8 show altered Wnt signaling, cell fate and proliferation. How do these findings shape our understanding of this disease?

See also: Article by Durak et al.

JOBS of the week
Post-Doctoral Fellow in Neuroscience
Washington University School of Medicine
Post-Doctoral Fellow in Neuroscience, Optogenetics, and Imaging
Washington University School of Medicine
Neuroscience Faculty Member-University of Illinois at Urbana Champaign
University of Illinois at Urbana/Champaign
Faculty Position In Theoretical Neuroscience
Cold Spring Harbor Laboratory (CSHL)
Postdoctoral position in Neuroscience: Neural Circuits underlying behavior
Max Planck Society, caesar
More Science jobs from
2nd International Brain Stimulation Conference
5th - 8th March 2017
Barcelona, Spain
More science events from
Labeled Iba1 Antibodies

At the request of our customers, Wako's antibody for the microglial marker Iba1, is now available in labeled forms. Choose from 2 types - one conjugated with Biotin and the other with Red Fluorochrome (635). This can eliminate the need for a secondary antibody, and provides reduced background.



Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia   pp1433 - 1441
Giulio Genovese, Menachem Fromer, Eli A Stahl, Douglas M Ruderfer, Kimberly Chambert et al.
Using whole-exome sequencing, the authors identified 244,246 coding-sequence and splice-site ultra-rare variants (URVs) and found that gene-disruptive and putatively protein-damaging URVs were significantly more abundant in schizophrenia cases than in controls. The excess of protein-compromising URVs was concentrated in brain-specific genes, particularly in neuronally expressed genes whose proteins are located at the synapse.

See also: News and Views by Gratten

Gene expression elucidates functional impact of polygenic risk for schizophrenia   pp1442 - 1453
Menachem Fromer, Panos Roussos, Solveig K Sieberts, Jessica S Johnson, David H Kavanagh et al.
The CommonMind Consortium sequenced RNA from dorsolateral prefrontal cortex of subjects with schizophrenia (N=258) and control subjects (N=279), creating a resource of gene expression and its genetic regulation. Using this resource, they found that [sim]20% of schizophrenia loci have variants that may contribute to altered gene expression and liability.

See also: News and Views by Albert

Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder   pp1454 - 1462
Arjun Krishnan, Ran Zhang, Victoria Yao, Chandra L Theesfeld, Aaron K Wong et al.
Autism spectrum disorder is a complex disease with a strong genetic basis that remains under-characterized by current genetics studies. Here, the authors use a computational approach based on a human brain-specific gene network to predict autism-associated genes across the genome and further delineate their functional and developmental characteristics.

Genome-wide, integrative analysis implicates microRNA dysregulation in autism spectrum disorder   pp1463 - 1476
Ye E Wu, Neelroop N Parikshak, T Grant Belgard and Daniel H Geschwind
The authors performed genome-wide microRNA (miRNA) expression profiling in post-mortem brains from individuals with autism spectrum disorder (ASD) and controls, and identified miRNAs and co-regulated modules perturbed in ASD.

Chd8 mediates cortical neurogenesis via transcriptional regulation of cell cycle and Wnt signaling   pp1477 - 1488
Omer Durak, Fan Gao, Yea Jin Kaeser-Woo, Richard Rueda, Anthony J Martorell et al.
De novo mutations in CHD8 are associated with autism spectrum disorder, but the basic biology of CHD8 remains poorly understood. Here the authors find that Chd8 knockdown during cortical development results in defective neural progenitor proliferation and differentiation that ultimately manifests in abnormal neuronal morphology and behaviors in adult mice.

See also: News and Views by Breuss & Gleeson

Ucn3 and CRF-R2 in the medial amygdala regulate complex social dynamics   pp1489 - 1496
Yair Shemesh, Oren Forkosh, Mathias Mahn, Sergey Anpilov, Yehezkel Sztainberg et al.
Social encounters are associated with varying degrees of stress. The authors show that modulation of stress system components in the medial amygdala alters preference for familiar vs. novel conspecifics. Inhibition of the relevant circuit in a group of familiar mice kept under semi-natural conditions increased pro-social behavior.

Histone deacetylase 3 associates with MeCP2 to regulate FOXO and social behavior   pp1497 - 1505
Alexi Nott, Jemmie Cheng, Fan Gao, Yuan-Ta Lin, Elizabeta Gjoneska et al.
Mutations in MECP2 cause Rett syndrome. The authors show that a MeCP2-HDAC3 complex positively regulates a subset of neuronal genes through FOXO recruitment and deacetylation, and that HDAC3 loss contributes to cognitive and social deficits in mice. Rett-patient-derived cells exhibited similar HDAC3-FOXO-mediated transcriptional impairments and were rescued by gene editing.

MeCP2 and histone deacetylases 1 and 2 in dorsal striatum collectively suppress repetitive behaviors   pp1506 - 1512
Melissa Mahgoub, Megumi Adachi, Kanzo Suzuki, Xihui Liu, Ege T Kavalali et al.
Loss of Hdac1 and Hdac2 in adult brain is detrimental to neuronal survival and triggers dysregulation of Sapap3 in the striatum in a MeCP2-dependent manner that results in an exacerbated repetitive behavior phenotype.

Foxp2 controls synaptic wiring of corticostriatal circuits and vocal communication by opposing Mef2c   pp1513 - 1522
Yi-Chuan Chen, Hsiao-Ying Kuo, Ulrich Bornschein, Hiroshi Takahashi, Shih-Yun Chen et al.
Chen et al. found that Foxp2 interacts with Mef2c to wire synaptic circuits linking neocortex to basal ganglia. The study analyzes the basics of circuit wiring underlying vocal communication.

Open for Submissions 

An interdisciplinary journal dedicated to publishing high-quality open research relevant to all aspects of schizophrenia and psychosis. 

Explore the benefits of submitting your next research article



Multimodal population brain imaging in the UK Biobank prospective epidemiological study   pp1523 - 1536
Karla L Miller, Fidel Alfaro-Almagro, Neal K Bangerter, David L Thomas, Essa Yacoub et al.
The UK Biobank combines detailed phenotyping and genotyping with tracking of long-term health outcomes in a large cohort. This study describes the recently launched brain-imaging component that will ultimately scan 100,000 individuals. Results from the first 5,000 subjects are reported, including thousands of associations, population modes and hypothesis-driven results.

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

Label Cloud

Technology (1097) News (595) Military (498) Microsoft (492) Business (487) Developer (382) Music (351) Software (318) Audio (316) Government (308) Security (300) Love (262) Books (257) Apple (236) Dungeons and Dragons (228) Funny (209) Google (194) Yahoo (186) Mobile (179) Storage (178) Adobe (176) Wishlist (159) Astrology (137) Local (137) Art (134) Investing (125) Shopping (124) AMD (105) Hardware (105) Neatorama (94) Blogger (93) Education (72) Movies (61) Mozilla (61) Dictionary (59) Weather (48) Video Games (44) Television (36) VoIP (25) meta (23) Holidays (14) Entertainment (12) Christian (11)